Immunic Therapeutics Secures $5.1M to Accelerate Development of Novel Oral Autoimmune Therapies

Immunic Therapeutics (Nasdaq: IMUX) is proud to announce the successful raising of $5,100,000 in its most recent funding round—a significant milestone that reinforces its commitment to transforming the landscape of chronic inflammatory and autoimmune disease treatment. As a pioneering biotechnology company, Immunic develops a robust clinical pipeline of orally administered, small molecule therapies that aim to provide patients with more convenient, effective, and less invasive alternatives compared to traditional treatments. This infusion of capital will be strategically deployed to accelerate research and clinical development efforts, with the primary focus on advancing its promising portfolio of clinical candidates toward new phase trials. The funds will not only support ongoing studies but also enable the expansion of preclinical research initiatives designed to explore innovative therapeutic mechanisms, ultimately positioning Immunic to address unmet medical needs and improve patient outcomes. With a clear vision to innovate and a dedication to science-driven solutions, Immunic is committed to enhancing treatment options for individuals suffering from chronic inflammatory and autoimmune conditions. Investors and partners are encouraged to stay informed about the company’s journey and future developments by visiting the official website and reviewing the privacy policy available at https://imux.com/privacy-policy/. This strategic funding round marks an exciting chapter in Immunic’s evolution, reaffirming its role as a leader in the biotech sector and enhancing its capacity to deliver groundbreaking therapies that could redefine standard care practices in autoimmune and inflammatory disorders.